Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie for å evaluere bivirkningene og effektiviteten av intravenøs (IV) av telisotuzumab adizutecan i kombinasjon med IV oksaliplatin, fluorouracil, folinsyre/leucovorin, bevacizumab, panitumumab hos voksne deltakere med metastatisk kolorektal kreftkreft (AndroMETa-CRC)

23. oktober 2026 oppdatert av: AbbVie

En fase 2, åpen, randomisert, masterprotokollstudie for å evaluere sikkerhet og effekt av flere behandlingskombinasjoner med telisotuzumab adizutecan hos personer med metastatisk kolorektal kreft

CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combination with oxaliplatin, fluorouracil (5FU), leucovorin (LV) (FOLFOX), and bevacizumab or panitumumab.

Telisotuzumab adizutecan is an investigational drug being developed for the treatment of mCRC. Fluorouracil and leucovorin are drugs approved for the treatment of mCRC. This study will be divided into two stages, with the first stage treating participants with increasing doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. Participants will then be randomized into 3 groups called treatment arms where one group will receive one of two optimized doses of telisotuzumab adizutecan from the dose escalation phase with FOLFOX and bevacizumab or 5FU/LV and panitumumab, or a comparator of FOLFOX and bevacizumab or panitumumab. Approximately 390 adult participants with mCRC will be enrolled in the study in 100 sites worldwide.

In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive FOLFOX or receive 5FU/LV, but with one of two optimized doses of telisotuzumab adizutecan, or a comparator of FOLFOX and bevacizumab/pantitumumab. The study will run for a duration of approximately 6 years.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

390

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • New South Wales
      • Sydney, New South Wales, Australia, 2109
        • Rekruttering
        • Macquarie University /ID# 271514
    • Queensland
      • South Brisbane, Queensland, Australia, 4101
        • Rekruttering
        • Mater Misericordiae /ID# 270694
        • Ta kontakt med:
          • Site Coordinator
          • Telefonnummer: +61731632341
    • South Australia
      • Woodville South, South Australia, Australia, 5011
        • Rekruttering
        • The Queen Elizabeth Hospital /ID# 270693
    • Victoria
      • Heidelberg, Victoria, Australia, 3084
        • Rekruttering
        • Austin Health /ID# 270692
    • Western Australia
      • Nedlands, Western Australia, Australia, 6009
        • Rekruttering
        • One Clinical Research /ID# 270695
      • São Paulo, Brasil, 04014-002
        • Rekruttering
        • Nucleo De Pesquisa Clinica Da Rede Sao Camilo /ID# 272311
      • São Paulo, Brasil, 01401-002
        • Rekruttering
        • Instituto D Or De Pesquisa E Ensino - Regional Sao Paulo /ID# 270546
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brasil, 41253-190
        • Rekruttering
        • Hospital Sao Rafael /ID# 271681
    • Rio Grande do Sul
      • Ijuí, Rio Grande do Sul, Brasil, 98700-000
        • Rekruttering
        • Oncosite - Centro de Pesquisa Clinica em Oncologia /ID# 270147
    • São Paulo
      • Barretos, São Paulo, Brasil, 14784-400
        • Rekruttering
        • Hospital De Amor /ID# 271874
      • São José do Rio Preto, São Paulo, Brasil, 15090-000
        • Rekruttering
        • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 271651
    • Alberta
      • Calgary, Alberta, Canada, T2N 5G2
        • Rekruttering
        • Arthur J.E Child Comprehensive Cancer Centre /ID# 269809
      • Edmonton, Alberta, Canada, T6G 1Z2
        • Rekruttering
        • Cross Cancer Institute. /ID# 272711
    • Ontario
      • London, Ontario, Canada, N6A 5W9
        • Rekruttering
        • London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 270680
      • Toronto, Ontario, Canada, M5G 2M9
        • Rekruttering
        • Princess Margaret Cancer Centre /ID# 268715
    • Quebec
      • Montreal, Quebec, Canada, H1T 2M4
        • Rekruttering
        • Universite de Montreal - Hopital Maisonneuve-Rosemont /ID# 271368
    • California
      • Duarte, California, Forente stater, 91010
        • Rekruttering
        • City of Hope National Medical Center /ID# 270255
      • Santa Monica, California, Forente stater, 90404
        • Rekruttering
        • UCLA - Santa Monica /ID# 270621
    • Connecticut
      • New Haven, Connecticut, Forente stater, 06510
        • Rekruttering
        • Yale New Haven Hospital /ID# 270565
    • Florida
      • Orlando, Florida, Forente stater, 32803
        • Rekruttering
        • AdventHealth Orlando /ID# 270789
    • Georgia
      • Marietta, Georgia, Forente stater, 30060
        • Rekruttering
        • Northwest Georgia Oncology Centers /ID# 270245
    • Illinois
      • Chicago, Illinois, Forente stater, 60637
        • Rekruttering
        • University of Chicago Medical Center /ID# 271688
      • Hinsdale, Illinois, Forente stater, 60521
        • Rekruttering
        • Hope And Healing Cancer Services /ID# 271562
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02215
        • Rekruttering
        • Dana-Farber Cancer Institute /ID# 270624
    • Michigan
      • Ann Arbor, Michigan, Forente stater, 48109-5000
        • Rekruttering
        • University Of Michigan /ID# 270790
    • Missouri
      • Kansas City, Missouri, Forente stater, 64111
        • Rekruttering
        • Saint Lukes Hospital of Kansas City /ID# 270633
    • Nebraska
      • Omaha, Nebraska, Forente stater, 68130
        • Rekruttering
        • Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271646
    • North Carolina
      • Chapel Hill, North Carolina, Forente stater, 27514
        • Rekruttering
        • University of North Carolina at Chapel Hill /ID# 267786
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45245
        • Rekruttering
        • Oncology Hematology Care - Eastgate /ID# 271493
    • Texas
      • Austin, Texas, Forente stater, 78705
        • Rekruttering
        • Texas Oncology - Austin Midtown /ID# 271354
      • Webster, Texas, Forente stater, 77598
        • Rekruttering
        • Texas Oncology - Deke Slayton Cancer Center /ID# 271355
    • Virginia
      • Fairfax, Virginia, Forente stater, 22031
        • Rekruttering
        • Virginia Cancer Specialists - Fairfax /ID# 271351
    • Washington
      • Seattle, Washington, Forente stater, 98109
        • Rekruttering
        • University Of Washington /ID# 271298
      • Paris, Frankrike, 75015
        • Rekruttering
        • Hopital Europeen Georges Pompidou /ID# 270224
    • Hauts-de-France
      • Lille, Hauts-de-France, Frankrike, 59037
        • Rekruttering
        • Centre Hospitalier Regional Universitaire de Lille - Hopital Claude Huriez /ID# 270222
    • New Aquitaine
      • Poitiers, New Aquitaine, Frankrike, 86021
        • Rekruttering
        • Centre Hospitalier Universitaire de Poitiers /ID# 270225
    • Pays de la Loire Region
      • Nantes, Pays de la Loire Region, Frankrike, 44000
        • Rekruttering
        • Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 270221
    • Île-de-France Region
      • Paris, Île-de-France Region, Frankrike, 75013
        • Rekruttering
        • Hopital Pitie Salpetriere /ID# 270220
      • Thessaloniki, Hellas, 54639
        • Rekruttering
        • Theagenio Cancer Hospital /ID# 269640
    • Attica
      • Chaïdári, Attica, Hellas, 12462
        • Rekruttering
        • University General Hospital Attikon /ID# 268555
      • Nea Kifissia, Attica, Hellas, 14564
        • Rekruttering
        • General Oncology Hospital of Kifisia Agioi Anargyroi /ID# 268762
      • Piraeus, Attica, Hellas, 18547
        • Rekruttering
        • Metropolitan Hospital /ID# 269636
    • Thessaloniki
      • Panórama, Thessaloniki, Hellas, 55236
        • Rekruttering
        • St. Luke's Hospital /ID# 269963
      • Haifa, Israel, 3109601
        • Rekruttering
        • Rambam Health Care Campus- Haifa /ID# 268006
      • Jerusalem, Israel, 9103102
        • Rekruttering
        • Shaare Zedek Medical Center /ID# 268009
      • Jerusalem, Israel, 91120
        • Rekruttering
        • Hadassah Medical Center-Hebrew University /ID# 268007
    • Central District
      • Petah Tikva, Central District, Israel, 4941492
        • Rekruttering
        • Rabin Medical Center. /ID# 268008
    • Tel Aviv
      • Tel Aviv, Tel Aviv, Israel, 6423906
        • Rekruttering
        • Tel Aviv Sourasky Medical Center /ID# 268010
    • Milano
      • Milan, Milano, Italia, 20162
    • Napoli
      • Naples, Napoli, Italia, 80138
        • Rekruttering
        • Azienda Ospedaliera Universitaria Luigi Vanvitelli /ID# 269191
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan, 464-8681
        • Rekruttering
        • Aichi Cancer Center /ID# 270113
    • Chiba
      • Kashiwa-shi, Chiba, Japan, 277-8577
        • Rekruttering
        • National Cancer Center Hospital East /ID# 270114
    • Kanagawa
      • Kawasaki-shi, Kanagawa, Japan, 216-8511
        • Rekruttering
        • St Marianna University School Of Medicine /ID# 270111
    • Miyagi
      • Sendai, Miyagi, Japan, 980-8574
        • Rekruttering
        • Tohoku University Hospital /ID# 270966
    • Tokyo
      • Chuo-Ku, Tokyo, Japan, 104-0045
        • Rekruttering
        • National Cancer Center Hospital /ID# 270112
      • Rio Piedras, Puerto Rico, 00935
        • Rekruttering
        • Pan American Center for Oncology Trials - Rio Piedras /ID# 268809
      • San Juan, Puerto Rico, 00917-5022
        • Rekruttering
        • Puerto Rico Medical Research Center /ID# 268825
      • Barcelona, Spania, 08035
        • Rekruttering
        • Hospital Universitario Vall de Hebron /ID# 270191
      • Madrid, Spania, 28027
        • Rekruttering
        • Clinica Universidad de Navarra - Madrid /ID# 269754
      • Madrid, Spania, 28046
        • Rekruttering
        • Hospital Universitario La Paz /ID# 269730
      • Valencia, Spania, 46010
        • Rekruttering
        • Hospital Clinico Universitario de Valencia /ID# 269805
    • Cantabria
      • Santander, Cantabria, Spania, 39008
        • Rekruttering
        • Hospital Universitario Marques de Valdecilla /ID# 269732
    • Navarre
      • Pamplona, Navarre, Spania, 31008
        • Rekruttering
        • Clinica Universidad de Navarra - Pamplona /ID# 269753
      • Manchester, Storbritannia, M20 4BX
        • Rekruttering
        • The Christie NHS Foundation Trust - Christie Hospital /ID# 271561
    • Greater London
      • London, Greater London, Storbritannia, E1 2ES
        • Rekruttering
        • Barts Health NHS Trust /ID# 271189
    • Oxfordshire
      • Oxford, Oxfordshire, Storbritannia, OX3 9DU
        • Rekruttering
        • Oxford University Hospitals Nhs Foundation Trust /ID# 272486
    • Surrey
      • Sutton, Surrey, Storbritannia, SM2 5PT
        • Rekruttering
        • The Royal Marsden - Sutton /ID# 271172
    • West Midlands
      • Birmingham, West Midlands, Storbritannia, B9 5SS
        • Rekruttering
        • Heartlands Hospital - University Hospitals Birmingham /ID# 271178
      • Kaohsiung City, Taiwan, 807
        • Rekruttering
        • Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 269724
      • Kaohsiung City, Taiwan, 833
        • Rekruttering
        • Kaohsiung Chang Gung Memorial Hospital /ID# 269726
      • Tainan, Taiwan, 704
        • Rekruttering
        • National Cheng Kung University Hospital /ID# 270835
      • Taipei, Taiwan, 112
        • Rekruttering
        • Taipei Veterans General Hospital /ID# 269718
      • Taipei, Taiwan, 100
        • Rekruttering
        • National Taiwan University Hospital /ID# 269717
      • Taoyuan City, Taiwan, 333
        • Rekruttering
        • Linkou Chang Gung Memorial Hospital /ID# 269725
      • Brno, Tsjekkia, 656 53
        • Rekruttering
        • Masarykuv onkologicky ustav v Brne /ID# 268779
      • Hradec Králové, Tsjekkia, 500 05
        • Rekruttering
        • Fakultni nemocnice Hradec Kralove - Sokolska /ID# 268773
    • Praha 17
      • Prague, Praha 17, Tsjekkia, 128 00
        • Rekruttering
        • Vseobecna Fakultni nemocnice v Praze /ID# 268775
    • Praha 5
      • Prague, Praha 5, Tsjekkia, 150 06
        • Rekruttering
        • Fakultni nemocnice Motol a Homolka /ID# 268776
    • Praha, Hlavni Mesto
      • Prague, Praha, Hlavni Mesto, Tsjekkia, 140 59
        • Rekruttering
        • Fakultni Thomayerova nemocnice /ID# 269632
      • Salzburg, Østerrike, 5020
        • Rekruttering
        • Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 268874
      • Vienna, Østerrike, 1090
        • Rekruttering
        • Medizinische Universitaet Wien /ID# 268872
    • Styria
      • Graz, Styria, Østerrike, 8010
        • Rekruttering
        • Medizinische Universitaet Graz /ID# 268876

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Laboratory values meeting the criteria within the protocol.
  • Has measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.

Exclusion Criteria:

  • Prior systemic regimen containing c-Met targeting agent(s) (e.g., antibody, antibody drug conjugate, bispecific) and/or any topoisomerase inhibitor(s) (e.g., irinotecan).
  • History of other malignancies within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Substudy 1: Dose Escalation Telisotuzumab Adizutecan

Participants will receive various doses of telisotuzumab adizutecan in combination with a fixed dose of fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and bevacizumab as part of the approximately 6 year study duration.

Intravenous (IV) Infusion

IV Infusion

IV Infusion; IV Injection

IV Infusion

IV Infusion; IV Injection

Eksperimentell: Substudy 1: Dose Expansion Telisotuzumab Adizutecan High Dose

Participants will receive the high dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 year study duration.

Intravenous (IV) Infusion

IV Infusion

IV Infusion; IV Injection

IV Infusion

IV Infusion; IV Injection

Eksperimentell: Substudy 1: Dose Expansion Telisotuzumab Adizutecan Low Dose

Participants will receive the low dose of telisotuzumab adizutecandetermined in the dose expansion arm in combination with a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 year study duration.

Intravenous (IV) Infusion

IV Infusion

IV Infusion; IV Injection

IV Infusion

IV Infusion; IV Injection

Eksperimentell: Substudy 1: Dose Expansion Compatator

Participants will receive a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 year study duration.

IV Infusion

IV Infusion; IV Injection

IV Infusion

IV Infusion; IV Injection

Eksperimentell: Substudy 2: Dose Escalation Telisotuzumab Adizutecan

Participants will receive various doses of telisotuzumab adizutecan in combination with a fixed dose of fluorouracil (5-FU) and leucovorin (LV) and panitumumab as part of the approximately 6 year study duration.

Intravenous (IV) Infusion

IV Infusion; IV Injection

IV Infusion; IV Injection

IV Infusion

Eksperimentell: Substudy 2: Dose Expansion Telisotuzumab Adizutecan High Dose

Participants will receive the high dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of 5-FU/LV and panitumumab as part of the approximately 6 year study duration.

Intravenous (IV) Infusion

IV Infusion; IV Injection

IV Infusion; IV Injection

IV Infusion

Eksperimentell: Substudy 2: Dose Expansion Telisotuzumab Adizutecan Low Dose

Participants will receive the low dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of 5-FU/LV and panitumumab as part of the approximately 6 year study duration.

Intravenous (IV) Infusion

IV Infusion; IV Injection

IV Infusion; IV Injection

IV Infusion

Eksperimentell: Substudy 2: Dose Expansion Compatator

Participants will receive a fixed dose of FOLFOX and panitumumab as part of the approximately 6 year study duration.

IV Infusion; IV Injection

IV Infusion

IV Infusion; IV Injection

IV Infusion

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Objective Response (OR) as Assessed by the Investigator confirmed complete response (CR) or partial response (PR) as assessed by the investigator per response evaluation criteria in solid tumors (RECIST), version 1.1.
Tidsramme: Up to 24 Weeks

OR is defined as confirmed CR or PR as assessed by the investigator per RECIST, version 1.1.

Up to 24 Weeks
Number of Participants with Adverse Events (AE)s
Tidsramme: Up to Approximately 6 Years

An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

Up to Approximately 6 Years

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Progression-Free Survival (PFS) as Assessed by the Investigator
Tidsramme: Up to 22 Months

PFS is defined as the time from the first dose of study treatment to the first occurrence of radiographic progression based on RECIST version 1.1 as determined by the investigator or death from any cause, whichever occurs earlier.

Up to 22 Months
Duration of Response (DOR) as Assessed by the investigator
Tidsramme: Up to 14 Months

DOR is defined as the time from the first documented CR or PR to the first occurrence of radiographic progression per RECIST v1.1 as determined by the investigator or death from any cause, whichever occurs first.

Up to 14 Months
Overall Survival (OS)
Tidsramme: Up to Approximately 6 Years

OS is defined as the time from first dose of study treatment to the event of death from any cause.

Up to Approximately 6 Years
Disease Control (DC) as Assessed by the Investigator
Tidsramme: Up to Approximately 6 Years

DC is defined as best overall response of confirmed CR or confirmed PR, or stable disease (SD) based on RECIST, version 1.1 as determined by the investigator.

Up to Approximately 6 Years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: ABBVIE INC., AbbVie

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

24. april 2025

Primær fullføring (Antatt)

1. mars 2028

Studiet fullført (Antatt)

1. april 2028

Datoer for studieregistrering

Først innsendt

6. februar 2025

Først innsendt som oppfylte QC-kriteriene

6. februar 2025

Først lagt ut (Faktiske)

11. februar 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

27. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

23. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

IPD-delingstidsramme

For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Tilgangskriterier for IPD-deling

To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere